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SOCS6a b s t r a c t
This study aimed to test the exact functions and potential mechanisms of miR-17-5p in gastric can-
cer. Using real-time PCR, miR-17-5p was found to be expressed more highly in gastric cancer com-
pared with-normal tissues. Gain- and loss-of-function assays demonstrated that miR-17-5p
increased the proliferation and growth of gastric cancer cells in vitro and in vivo. Through reporter
gene and western blot assays, SOCS6 was shown to be a direct target of miR-17-5p, and proliferative
assays conﬁrmed that SOCS6 exerted opposing function to that of miR-17-5p in gastric cancer. In
short, miR-17-5p might function as a pro-proliferative factor by repressing SOCS6 in gastric cancer.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the regulation of the malignancies of multiple cancers. For exam-MicroRNAs (miRNAs) are non-coding RNAs that are as small as
19–22 nucleotides in length. miRNAs can work in association with
the RNA-induced silencing complex (RISC) to silence the expres-
sion of various genes by either inducing translational repression
or causing degradation of the mRNAs of the targeted genes [1,2].
In the last decade, it has been widely conﬁrmed that miRNAs can
modulate multiple key cellular processes in normal cells, including
cell growth, cell differentiation, cell cycle, and cell death. While in
cancers, miRNA can act as oncogenes or tumor suppressors to reg-
ulate multiple malignant phenotypes such as cancer drug resis-
tance, cancer cell proliferation, and cancer cell metastasis.
miR-17-5p is one of the members of the miRNA cluster of miR-
17-92 which contains seven members (miR-17-5p, miR-17-3p,
miR-20a, miR-19a, miR-19b, miR-92a and miR-18a) and was previ-
ously identiﬁed as an oncomiR-1 [3]. miR-17-5p is also one of the
most studied miRNAs related to cancers in this cluster. Compared
with normal tissues, higher expression of miR-17-5p has been
found in various cancers such as colorectal cancer, gastric cancer,
hepatocellular carcinoma, glioma, basal cell carcinoma, and pan-
creatic cancer [4–9]. miR-17-5p is also functionally involved inple, in colorectal cancer, miR-17-5p regulates tumorigenesis, pro-
liferation, invasiveness, and cell cycle progression by targeting
various tumor suppressors [10–12]. In pancreatic cancer, cells
transfected with miR-17-5p precursors showed signiﬁcantly
higher cell growth ratios than the corresponding control cells [13].
Although the miR-17-92 cluster has been established as oncom-
iRs and miR-17-5p was identiﬁed to have oncogenic abilities in
several cancers, the oncogenic contribution of miR-17-5p in gastric
cancer has not been assigned. The present study ﬁrst found that
miR-17-5p was highly expressed in gastric cancer tissues com-
pared with the adjacent normal tissues. To test the function of
the highly expressed miR-17-5p in gastric cancer, stable and tran-
sient transfection were used, and the in vitro and in vivo malignant
phenotypes of gastric cancer cells were tested. Furthermore, SOCS6
was conﬁrmed as a direct target of miR-17-5p. Our ﬁndings pro-
vide evidence for miR-17-5p’s function in gastric cancer and have
important implications for understanding the mechanisms of gas-
troenterological disorders resulting from altered modulation of
miRNA pathways.
2. Materials and methods
2.1. Ethics statement
For the analyzed tissue specimens, all patients were given con-
sent to inform the use of excessive pathological specimens for lab-
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study were approved by the Protection of Human Subjects Com-
mittee of Xijing Hospital. The use of the human pathological spec-
imens was approved by the Fourth Military Medical University’s
institutional review board and conformed to the Helsinki Declara-
tion and the local legislation. Informed consent forms were signed
by patients to offer FFPE (Formalin-ﬁxed, parafﬁn-embedded) sam-
ples from gastrectomies to use in this study. For animal experi-
ments, all procedures were performed in accordance with the
guidelines of Institutional Animal Care and Use Committee of the
Experimental Animal Center of the Fourth Military Medical
University.
2.2. Cell culture and reagents
The cell line SGC7901 for human gastric adenocarcinoma was
obtained from the Academy of Military Medical Science, and the
human gastric adenocarcinoma cell line MKN28 and
human embryonic kidney 293 cells were obtained from the Shang-
hai Cell Bank (Shanghai, China). These cell lines were preserved in
our institute. The ﬁreﬂy luciferase stable expressing SGC7901-Luc
cells were generated and preserved in our lab. All of the cells were
grown in RPMI1640 (Invitrogen, Carlsbad, CA, USA) and were sup-
plemented with 10% heat-inactivated fetal calf serum (FCS) at
37 C with 5% CO2 in a humidiﬁed incubator (Forma Scientiﬁc, Mar-
ietta, OH, USA). The precursors (pre-miRs) and inhibitors (miR-
inhs) of miR-17-5p were obtained from Applied Biosystems (Invit-
rogen, Carlsbad, CA, USA).
2.3. Lentivirus miR-17-5p infection and stable cells
The lenti-viral system with EGFP expressing miR-17-5p (lenti-
miR-17-5p) and the negative control lenti-vector (lenti-NC) were
purchased from Genechem (Shanghai Genechem Co., Ltd., Shang-
hai, China). The gastric cancer cell lines SGC7901, SGC7901-Luc
and MKN28 were infected with lenti-miR-17-5p or lenti-NC,
according to the manufacturer’s instructions, and stable cells were
isolated by ﬂow cytometry to sort EGFP-positive cells.
2.4. In vitro cell proliferation assay
The in vitro cell proliferation assay was performed as described
previously [14]. A total of 103 cells were used for the assays in
200 ll of complete medium. The cultures were assayed each day
and read at a 490 nm absorbance (A490) on a micro-plate reader
(168-1000 Model 680, Bio-Rad Laboratories, Inc., Hercules, Califor-
nia, USA). Each experiment was performed in triplicate and
repeated 3 times.
2.5. Animals and in vivo tumorigenecity assays
Four- to six-week-old BALB/C nude mice were feed in the
Experimental Animal Center of the Fourth Military Medical Univer-
sity (Xi’an, Shaanxi Province, China) and were handled using the
best humane practices and cared for in accordance with the NIH
Animal Care Institutional Guidelines. Fireﬂy luciferase labeled
SGC7901 cells, —SGC7901-Luc, were infected with lenti-miR-17-
5p or lenti-NC, as described above, and stable clones were isolated.
To detect the tumorigenecity of the cells in nude mice, 5  106 cells
containing lenti-miRs were injected subcutaneously into the back
of each mouse; and each group contained six mice. After injection,
bioluminescent signals were detected twice a week using the IVIS
100 Imaging System (Xenogen, Hopkinton, MA, USA). Five minutes
before imaging, the mice were injected intraperitoneally with
100 mg/kg D-luciferin. The mice were killed four weeks after injec-
tion of gastric cancer cells. For histological analysis, the tumorsgenerated from the nude mice were harvested and ﬁxed in 10% for-
malin before parafﬁn embedding and were then sectioned and
stained using H&E staining.
2.6. Reporter gene assay
For the reporter gene assay, cells were plated in 12-well plates
and transfected with 2 lg of SOCS6 30-UTR luciferase reporter plas-
mids (S) or the SOCS6 30-UTR Anti-sense (AS) and the empty pGL3-
Control vector (Promega Biotech Co., Ltd., Beijing, China) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The cells were
also co-transfected with the pre-miRNAs (150 nM, Applied Biosys-
tems, Invitrogen, Carlsbad, CA, USA). Assays were performed 24 h
after transfection using the Dual Luciferase Reporter Assay system
(Promega Biotech Co., Ltd., Beijing, China), and ﬁreﬂy luciferase
activities were normalized to Renilla luciferase activities. A micr-
oRNA precursor molecule control from Applied Biosystems (Invit-
rogen, Carlsbad, CA, USA) was used as one of the negative miRNA
controls and was referred to as pre-miR-NC, and the miR-150 pre-
cursor molecule was used as a negative control. All experiments
were performed in triplicate.
2.7. Western blot analysis
To determine the expressed protein levels, log-phase cells were
harvested from 90-mm culture plates, lysed in RIPA lysis buffer
(150 mM NaCl, 50 mM Tris–HCl (pH 8.0), 0.1% SDS, 2 mM EDTA,
1 mM PMSF, 1% NP40, 5 lg/ml aprotinin, and 1 lg/ml leupeptin)
on ice, and then were centrifuged at 12000 rpm for 10 min. Total
proteins were resolved using 12% SDS–PAGE (Bio-Rad Laboratories,
Inc, Hercules, CA, USA) and blotted onto nitrocellulose membranes
(Amersham Biosciences Corp., Pittsburgh, PA, USA). The nitrocellu-
lose membranes were then blocked with 10% non-fat powdered
milk at room temperature for 2 h and incubated overnight with
primary antibody: anti- SOCS6 (1:1000; Abcam plc. Cambridge,
MA, USA) or anti-b-actin antibody (1:2000; Sigma–Aldrich
Co., Louis, MO, USA). After three 5-min washes in Triethanola-
mine-Buffered Saline Solution with Tween (TBS-T), the membranes
were incubated with horseradish peroxidase (HRP) – conjugated
secondary antibodies (1:2000; Santa Cruz Biotechnology, Inc., Dal-
las, TX, USA) for 4 h at room temperature and then washed again in
TBS-T and visualized with an enhanced chemi-luminescence kit
(ECL-kit, Santa Cruz Biotechnology, Inc., Dallas, TX, USA). All exper-
iments were performed in triplicate.
2.8. RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA from cancer tissues was extracted from FFPE-
impeded tissue sections according to the manufacturer’s instruc-
tions (AM1975, Applied Biosystems, Invitrogen, Carlsbad, CA,
USA). Total RNA from cells or tumors from mice was extracted
using TRIZOL (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s instructions, with RNase-free DNase. Reverse tran-
scription was performed according to the manufacturer’s instruc-
tions (D350A, TaKaRa Biotechnology (DALIAN), Co., Ltd., DaLian,
Liaoning Province, China). qRT-PCR was performed to determine
the expression levels of each miRNA using the exact sequences
(U to T) of the miRNAs as the forward primers and a unique q-
PCR primer from the cDNA Synthesis Kit as the reverse primer.
U6 was used as the internal control for the miRNAs, and beta-actin
was used as the internal control for SOCS6. Each plate contained
one cDNA sample for each primer as a calibration sample. In the
experiments with cell lines, the calibration sample was cDNAs
from a certain SGC7901 cell line. All experiments were performed
in triplicate. Gene expression was calculated as previously
reported [15].
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Continuous variables were compared by Student’s t test or the
ANOVA test. If the test result of the variance homogeneity between
the groups was signiﬁcant, the Mann–Whitney test was appropri-
ately adopted. In samples with small size (n < 30) and with non-
normal distribution and/or elevated dispersion, we also used
non-parametric statistics. The correlations among various genes
were analyzed with Spearman’s correlation analysis. Two-tailed
P-values < 0.05 were considered statistically signiﬁcant (⁄P < 0.05;
⁄⁄P < 0.01). All statistical analyses were conducted using the SPSS
software, version 14.0 (Chicago, Illinois, USA).
3. Results
3.1. miR-17-5p was over-expressed in gastric cancer tissues compared
with normal tissues
miR-17-5p was previously regarded as a member of the oncom-
iR-1 cluster and was over-expressed in various cancers. Therefore,
we wondered whether it is also over-expressed in gastric cancer
when compared with normal tissues. Real-time PCR was used toFig. 1. miR-17-5p is over-expressed in gastric cancer tissues compared with normal tiss
gastric cancer samples compared with adjacent normal tissues (⁄⁄P 6 0.01, ⁄P 6 0.05). Eac
the mean ± S.D. (B and C) Infection of lenti-miR-17-5p in SGC7901 (B) and MKN28 (C) ce
cytometry for GFP-positive cells to enrich the miR-17-5p overexpressing cells. (D) Su
SGC7901 and MKN28 was conﬁrmed using real-time PCR. The fold change was used to c
Each experiment was repeated at least 3 times. Error bars correspond to the mean ± S.D. (
cancer cell lines SGC7901 and MKN28 was conﬁrmed using real-time PCR. The fold cha
control (NC-inh). Each experiment was repeated at least 3 times. Error bars correspondtest the miR-17-5p expression in gastric cancer tissues and the
adjacent normal tissues using RNAs from 28 patients who under-
went gastrectomy and were followed up at Xijing Hospital during
2004–2008. We used 244Ct analysis to statistically describe the
expression levels of miR-17-5p. As shown in Fig. 1A, the results
veriﬁed that the expression of miR-17-5p was higher in 18 of 28
randomly selected human gastric cancer tissues compared with
the adjacent normal tissues. The data was also shown in a simplest
plot indicated in Supplementary Fig. 3.
To test if miR-17-5p expression is associated with the survival
of gastric cancer patients, we also compared the miRNA expression
data with the overall survival data of the gastric cancer patients’.
The results showed that miR-17-5p expression was not associated
with the overall survival of gastric cancer patients, with a P value of
0.264 and HR (95% CI) = 1.005 (0.996–1.013). To test the relation-
ship between miR-17-5p expression and the clinic pathological
statistics in gastric cancer patients, we performed a Mann–Whit-
ney test on the statistics on the clinic-pathology and expression
of miR-17-5p. However, the expression of miR-17-5p was neither
associated with the overall survival of gastric cancer patients nor
associated with clinic-pathological statistics such as age, gender,
TNM stage, lymph nodemetastasis, or remote metastasis, as shownues. (A) Real-time PCR shows the expression of miR-17-5p in 28 randomly selected
h experiment was independently repeated at least 3 times. Error bars correspond to
lls was conﬁrmed using GFP under a ﬂuorescence microscope and sorted using ﬂow
ccessful stable over-expression of lenti-miR-17-5p in the gastric cancer cell lines
alculate each of the values of miR-17-5p relative to the negative control (lenti-NC).
E) Successful transient knock down of miR-17-5p inhibitors (miR-inh) in the gastric
nge was used to calculate each of the values of miR-17-5p relative to the negative
to the mean ± S.D.
2058 Q. Wu et al. / FEBS Letters 588 (2014) 2055–2062in Supplementary Table 1. However, the expression of miR-17-5p
was associated with the differentiation degree of gastric cancer
(P = 0.003).
3.2. Over-expression of miR-17-5p promoted gastric cancer growth
and proliferation in vitro
To investigate whether miR-17-5p could have a functional
effect on cell growth and proliferation, we stably infected the gas-
tric cancer cell lines SGC7901 and MKN28 with lentivirus contain-
ing pre-miR-17-5p as shown in Fig. 1B and C. The successful over-
expression of the mature miR-17-5p was conﬁrmed via real-time
PCR (Fig. 1D). The basic expression of miR-17-5p in SGC7901 and
MKN28 cells was analyzed using real-time PCR and shown in Sup-
plementary Fig. 1. Using the MTT (Fig. 2A and B) and colony forma-
tion assays (Fig. 2C and D), we found that cells stably over-
expressing lenti-miR-17-5p proliferated faster than lenti-NC-
infected cells. To test the knock down function of these miRNAs,
we transiently transfected miR-17-5p inhibitors into the same gas-
tric cancer cell lines SGC7901 and MKN28 (Fig. 1E) and tested their
function using the above-mentioned proliferation assays. Con-
versely, using the MTT assay (Fig. 2A and B) and colony formation
assay (Fig. 2C and D), we foundmiR-17-5p inhibitors caused cancer
cells to proliferate slower than the negative control .To avoid the
cellular changes caused by experimental artifacts, we also per-
formed sense-transient transfections using miR-17-5p precursors
and tested the cell proliferative functions. Consistent with stably
expressing cells, the transient transfection of miR-17-5p promoted
proliferation, as shown by the MTT and colony formation assays
and indicated in Fig. 3A and B.Fig. 2. Over-expression of miR-17-5p promoted gastric cancer growth and proliferation
miR-17-5p and miR-17-5p inhibitors in SGC7901 (A) and MKN28 (B) gastric cancer cell
⁄⁄P 6 0.01, ⁄P 6 0.05). Each experiment was independently repeated at least 3 times. E
performed to evaluate the proliferative functions of lenti-miR-17-5p-infected cells or miR
and compared with the negative controls respectively (lenti-NC or NC-inh). Representati
(C) and the obtained colony numbers (D). (⁄⁄P 6 0.01). Each experiment was independe3.3. miR-17-5p exerted its function via targeting SOCS6
To identify direct targets of miR-17-5p for modulating growth
and proliferation in gastric cancer, bioinformatics analysis was
used. In silico analysis using the MiRanda software (http://
www.microrna.org/microrna/home.do) showed that the 30-UTR of
SOCS6 contains conserved putative target sites for miR-17-5p as
shown in Fig. 3C. To further validate this target site, the 30-UTR
of human SOCS6, in the sense (S) or antisense (AS) orientation,
was inserted downstream of the luciferase gene in the pGL3-Con-
trol vector, providing Luc-Sense and Luc-Anti-sense respectively,
which are referred to as Luc-S and Luc-AS, respectively in Fig. 3D.
Reporter gene assays showed that transfecting HEK-293 cells
with miR-17-5p signiﬁcantly decreased the expression of Luc-S,
but caused no effect on Luc-AS expression (Fig. 3D). In contrast,
miR-150 did not exhibit any effect on the expression of Luc-S,
(Fig. 3D), in accordance with the fact that the 30-UTR contains no
miR-150 target sites. To further prove the targeting of miR-17 on
SOCS6 professionally, we performed reporter gene assay using
the site-mutation of 30 UTR of SOCS6. As shown in Supplementary
Fig. 2, miR-17miRNAs could bind the wt sequence of SOCS6 30 UTR,
but could not bind to the mutated 30 UTR of SOCS6. In this case,
miR-150 miRNA also did not have effect on the expression of
SOCS6 30 UTR.
To evaluate the down-regulating effect of miR-17-5p on SOCS6,
we performedWestern blot analysis using anti-SOCS6 antibody. As
expected, transfecting SGC7901 cells with pre-miR-17-5p
decreased SOCS6 levels (Fig. 3E), whereas transfecting cells with
miR-17-5p inhibitory RNAs had the opposite effect. These ﬁndings
suggest that the miR-17-5p miRNA regulates SOCS6 expression
in vivo at the post-transcriptional level.in vitro. (A and B) Cell proliferation was measured using the MTT assay with lenti-
s and compared with that of the negative controls respectively (lenti-NC or NC-inh
rror bars correspond to the mean ± S.D. (C and D) Colony formation assays were
-17-5p inhibitor-transfected cells in SGC7901 (A) and MKN28 (B) gastric cancer cells
ve images show the colony intensities of cells using 150 cells/well in 24-well plates
ntly repeated at least 3 times. Error bars correspond to the mean ± S.D.
Fig. 3. miR-17-5p exert its function via targeting SOCS6. (A) Cell proliferation of pre-miR-17-5p-transfected SGC7901 gastric cancer cells was measured using MTT assay and
compared with the negative control (pre-NC) (⁄⁄P 6 0.01). Each experiment was independently repeated at least 3 times. Error bars correspond to the mean ± S.D. (B) Colony
formation assays were performed to evaluate the proliferative functions of pre-miR-17-5p-transfected cells compared with the negative control (pre-NC) in SGC7901 cells.
The obtained colony numbers are shown (⁄⁄P 6 0.01). Each experiment was independently repeated at least 3 times. Error bars correspond to the mean ± S.D. (C) Schematic
representation of the SOCS6 30-UTR constructs. The conserved putative target sites for miR-17-5p miRNAs are indicated. (D) Luciferase assays were performed for SOCS6 in
the sense (S) and antisense (AS) orientations, as indicated. Bars indicate the ratios of the ﬁreﬂy luciferase (normalized to Renilla luciferase) activity that was measured
following transfection with miR-17-5p pre-miRNAs to that obtained following transfection with the pre-miR control (pre-NC) for the same construct (⁄⁄P 6 0.01, compared
with the AS group, t test). Each experiment was repeated at least 3 times. Error bars correspond to the mean ± S.D. (E) Western blot showing the changes in SOCS6 protein
levels after transient transfection of miR-17-5p precursors or inhibitors compared with the negative controls (pre-NC or NC-inh, respectively).
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mice
To validate the results of the in vitro cell proliferation assays,
we performed in vivo assays to evaluate the tumorigenic effect of
miR-17-5p in BALB/C nude mice using a luciferase-labeled lenti-
miR-17-5p-infected SGC7901-Luc cell line. The expression efﬁ-
ciency of miR-17-5p was conﬁrmed by real-time PCR, as shown
in Fig. 4A The results showed that lenti-miR-17-5p-infected cells
showed a pro-proliferative tendency in nude mice: stronger lucif-
erase signals on tumors generated from lenti-miR-17-5p-infected
cells were observed compared with the lenti-NC infected group
as indicated in Fig. 4B and C.
The histological analyses of the tumors were conﬁrmed using
H&E staining (Fig. 4D). Immunohistochemistry showed that the
expression of the miR-17-5p target gene SOCS6 was decreased in
the lenti-miR-17-5p – treated group compared with the NC-treated
group, as indicated in Fig. 4D. Real-time PCR was further used to
determine the expression of miR-17-5p in these tumors. The
results showed that tumors injected with lenti-miR-17-5p-infected
SGC7901-Luc cells exhibited increased expression of miR-17-5p
compared with the NC-treated group, as shown in Fig. 4E.
3.5. Over-expression of SOCS6 without its 30 UTR impaired the miR-17-
5p effects
To validate that SOCS6 is a target of miR-17-5p, we performed
real-time PCR using RNAs from 28 paired malignant and normal
tissues. As shown in Fig. 5A, the expression of SOCS6 adversely cor-
related with the expression of miR-17-5p (P = 0.01).To further prove that SOCS6 is a downstream target of miR-17-
5p, we performed cell proliferation assays using SGC7901 cells
transfected with pre-NC, pre-miR-17-5p alone, or pre-miR-17-5p
with SOCS6 without its 30UTR. The results from MTT (Fig. 5B)
and colony formation assays (Fig. 5C and D) showed that co-trans-
fection of SOCS6 without its 30UTR restricted the effects of pre-
miR-17-5p transfection alone. In another word, the over-expres-
sion of miR-17-5p was rescued by over-expression of SOCS6 with-
out its 30UTR.
4. Discussion
miRNAs are non-coding RNAs that are 19–24nt in size [1]. The
small molecular size of these RNAs makes it easier to transfer them
into mammal bodies. In recent years, miRNAs have emerged as
important regulators in the development of cancers [16]. Gastric
cancer is the second largest cancer worldwide. However, the
underlying mechanisms in the development of gastric cancer have
not been fully elucidated. Understanding the molecules and path-
ways involved in the progression of gastric cancer will help in
developing new biomarkers for diagnosis and new targets for ther-
apeutic strategies. In the present study, we provided evidence that
miR-17-5p might play signiﬁcant roles in the growth and prolifer-
ation of gastric cancer.
Previous studies have found that miR-17-5p was over-
expressed in various cancers [4–9]. The potential function of
miR-17-5p was also partly explored in several studies. For exam-
ple, Ma et al. found that miR-17-5p is a key factor in regulating
colorectal cancer progression through regulating tumorigenesis
Fig. 4. Over-expression of miR-17-5p increased tumorigenicity in nude mice. (A) Successful over-expression of mature miR-17-5p in SGC7901-Luc cells was conﬁrmed by
real-time PCR. The relative fold change was used to calculate each of the values of miR-17-5p relative to the negative control. Each experiment was repeated at least 3 times.
Error bars correspond to the mean ± S.D. (B and C) Representative images of mice four weeks after injection using the IVIS 100 system (B) and the detected luciferase signals
(C). The left ﬂanks of the mice were treated with lenti-NC, and the right ﬂanks were treated with lenti-miR-17-5p. (⁄P 6 0.05 compared with lenti-NC infected cells, t test).
Error bars correspond to the mean ± S.D. (D) Hematoxylin and eosin staining (H&E staining) and immunohistochemistry staining for SOCS6 of tumors generated from mice
injected with lenti-miR-17-5p over-expressing cells or negative-control cells (lenti-NC). (E) The relative expression of miR-17-5p in tumors generated from mice injected
with lenti-miR-17-5p over-expressing cells or the negative control cells (lenti-NC) were measured using real-time PCR. (⁄⁄P 6 0.01, compared with lenti-NC-infected cells, t
test) Each experiment was repeated at least 3 times. Error bars correspond to the mean ± S.D.
Fig. 5. Over-expression of SOCS6 without its30 UTR impaired the miR-17-5p effects. (A) Correlation of SOCS6 expression with miR-17-5p expression in the 28 paired gastric
cancer samples. The SOCS6 expression was reversely correlated with miR-17-5p expression. (B) MTT assays were used to measure the proliferative abilities of cells co-
transfected with pre-miR-17-5p, pre-miR-17-5p with SOCS6 without its 30UTR (17 + SOCS6/3ko), or the negative control (pre-NC) in SGC7901 gastric cancer cells. (⁄⁄P 6 0.01,
⁄P 6 0.05). Each experiment was independently repeated at least 3 times. Error bars correspond to the mean ± S.D. (C and D) Colony formation assays were performed to
evaluate the proliferative functions of pre-miR-17-5p, pre-miR-17-5p with SOCS6 without its 30UTR (17 + SOCS6/3ko), and the negative control (pre-NC) in SGC7901 gastric
cancer cells. Representative images show the colony intensities of cells using 150 cells/well in 24-well plates (C) and the obtained colony numbers (D) (⁄⁄P 6 0.01). Each
experiment was independently repeated at least 3 times. Error bars correspond to the mean ± S.D.
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of miR-17-5p, and the Wnt/b-catenin pathway was subsequently
activated. By grouping the colorectal cancer patients in two large
cohorts and analysing the specimens, they also found that miR-
17 expression was higher in patients who had shorter overall sur-
vival rate [10,11]. Zhang et al. also found that the miRNAs miR-21,
miR-17-5p and miR-19a were elevated and STAT3 was activated in
colon cancer cells when introducing the overexpression of PRL-
3into the cancer cells. Subsequently, the miRNAs miR-21, miR-
17-5p and miR-19a were found to contribute to the proliferative
and invasive progression of colon cancer cells [11]. Up-regulated
miR-17-5p promotes cell proliferative ability, tumor progression
and cell cycle in colorectal carcinoma by targeting the tumor sup-
pressive RND3 gene [12]. In pancreatic cancer, miR-17-5p was
found to be overexpressed in cancer tissues compared with the
normal tissues, the expression of miR-17-5p was associated with
poor survival rate of pancreatic cancer patients. Moreover,
in vitro experiments showed that introducingmiR-17-5p precursor
into SUIT-2 and KP-2 pancreatic cancer cells had signiﬁcantly
higher cell growth rates and higher invading cells than the control
group, [13]. miR-17-5p [17] also was reported to promote human
breast cancer cell migrative and invasive abilities through down-
regulating of HBP1, and increases the migrative ability of hepato-
cellular carcinoma by regulating the p38 mitogen-activated pro-
tein kinase-heat shock protein 27 pathway [17]. In gastric cancer,
previous studies have found that expression of miR-17-5p can be
used as biomarkers in gastric cancer patients [18] however, the
exact roles of miR-17-5p in gastric cancer cells are not fully under-
stood. In the present study, we found that miR-17-5p is highly reg-
ulated in gastric cancer tissues and has a pro-proliferative function
in the development of cancer cells.
miR-17-5p has several reported targets that are associated with
cancer cell growth or cell cycle, such as E2F1, PKD2 and p21 [19–
21]. The present study found that the pro-proliferative gene SOCS6
is also a potential target of miR-17-5p. SOCS6 is a member of the
suppressors of cytokine signalling (SOCS) protein family which
consist of negative feedback regulators of cytokine-mediated sig-
naling in various tissues and have been demonstrated to play crit-
ical roles in tumorigenesis and tumor development in different
cancers. Previous studies have found that SOCS6 was down-regu-
lated in gastric cancer, liver cancer, and prostate cancer [22–25];
however, it was over expressed in breast cancer [26]. The differen-
tial expression of SOCS6 in various cancers might be due to the dif-
ferent features of cancers that are generated from different organs.
In prostate cancer, the down-regulation of SOCS6 tended to be
found in prostate cancer tissues with a higher Gleason score,
advanced pathological stage, positive metastasis, and positive
PSA failure; thus the dys-regulation of SOCS2 and SOCS6 may be
related with the aggressive progression of prostate cancer [25]. In
hepatocellular carcinoma, patients with low expression of SOCS2
and SOCS6 had poor prognosis. Moreover, multivariate analysis
showed that SOCS2 and SOCS6 down-regulation were independent
prognostic factors of overall and disease-free survival in hepatocel-
lular carcinoma, indicating that the reduced expression of SOCS2
and SOCS6 might become potential prognostic markers in hepato-
cellular carcinoma [24].
Functionally, SOCS6 was reported to be targeted by the onco-
genic miRNA miR-424-5p which can functionally increase the pro-
liferation, migration and invasion in pancreatic cancer cells,
indicating an anti-proliferative effect of SOCS6 in pancreatic cancer
[27]. The absence of SOCS6 promotes the Ba/F3 and UT-7 cell pro-
liferation that is induced by oncogenic internal tandem duplica-
tions of Flt3, which indicated that SOCS6 inhibited
cell proliferation through Flt3 activation and the Erk signaling
pathway [28]. In gastric cancer, SOCS6 ectopic expression sup-
pressed cell proliferation and colony formation through inducingthe intrinsic apoptotic pathway [23]. The present study consis-
tently showed that, in gastric cancer, SOCS6 is an anti-proliferative
factor that has the opposite effect of miR-17-5p. Additionally, the
fact that co-transfection of the miR-17-5p precursor and SOCS6
without its 30UTR impaired miR-17-5p functions in gastric cancer
proliferation further indicated the mutual interaction of miR-17-
5p with the 30UTR of SOCS6.
As a last remark, miRNAs have been prevalently recognized to
be a better choice for diagnostic or therapeutic targets because of
their small size, which makes delivery easier, and because one
miRNA has various targets and might modulate different path-
ways. Thus, targeting one miRNA might provide multiple effects
that other molecules cannot reach. However, the exact role of each
of the miRNAs in various cancers has not been speciﬁed. Only
when we can understand the functions, targets, and the side effects
of one miRNA in a certain cancer can we obtain better knowledge
on that certain miRNA and apply it in cancer therapy. The present
study provided evidence on the potential pro-proliferative function
of miR-17-5p in gastric cancer and the potential mechanisms
regarding this proliferation ability, which shed light on the under-
standing of the mechanisms of cancerous disorders resulting from
altered expression of miR-17-5p miRNAs.
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